SKAN Group AG

LSE:0SKN Stock Report

Market Cap: CHF 1.7b

SKAN Group Valuation

Is 0SKN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0SKN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0SKN (CHF74.8) is trading below our estimate of fair value (CHF86.14)

Significantly Below Fair Value: 0SKN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0SKN?

Key metric: As 0SKN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0SKN. This is calculated by dividing 0SKN's market cap by their current earnings.
What is 0SKN's PE Ratio?
PE Ratio51.7x
EarningsCHF 32.24m
Market CapCHF 1.67b

Price to Earnings Ratio vs Peers

How does 0SKN's PE Ratio compare to its peers?

The above table shows the PE ratio for 0SKN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.8x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
8.3x-15.2%UK£144.6m
GNS Genus
141.4x37.7%UK£1.1b
C4XD C4X Discovery Holdings
2.9x-88.3%UK£30.3m
0SKN SKAN Group
51.7x18.7%CHF 1.7b

Price-To-Earnings vs Peers: 0SKN is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the peer average (50.8x).

Price to Earnings Ratio vs Industry

How does 0SKN's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0SKN 51.7xIndustry Avg. 36.9xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0SKN is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the European Life Sciences industry average (36.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0SKN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0SKN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.7x
Fair PE Ratio23.8x

Price-To-Earnings vs Fair Ratio: 0SKN is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0SKN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 74.80
CHF 90.00
+20.3%
3.3%CHF 93.00CHF 87.00n/a2
Nov ’25CHF 77.30
CHF 90.00
+16.4%
3.3%CHF 93.00CHF 87.00n/a2
Oct ’25CHF 80.00
CHF 90.00
+12.5%
3.3%CHF 93.00CHF 87.00n/a2
Sep ’25CHF 81.00
CHF 97.50
+20.4%
10.8%CHF 108.00CHF 87.00n/a2
Aug ’25CHF 79.70
CHF 97.50
+22.3%
10.8%CHF 108.00CHF 87.00n/a2
Jul ’25CHF 80.00
CHF 97.50
+21.9%
10.8%CHF 108.00CHF 87.00n/a2
Jun ’25CHF 80.40
CHF 95.67
+19.0%
9.4%CHF 108.00CHF 87.00n/a3
May ’25CHF 82.24
CHF 91.33
+11.1%
15.2%CHF 108.00CHF 74.00n/a3
Apr ’25CHF 85.10
CHF 91.33
+7.3%
15.2%CHF 108.00CHF 74.00n/a3
Mar ’25CHF 82.17
CHF 91.33
+11.2%
15.2%CHF 108.00CHF 74.00n/a3
Feb ’25CHF 75.81
CHF 91.33
+20.5%
15.2%CHF 108.00CHF 74.00n/a3
Jan ’25CHF 81.01
CHF 91.33
+12.7%
15.2%CHF 108.00CHF 74.00n/a3
Dec ’24CHF 78.20
CHF 91.33
+16.8%
15.2%CHF 108.00CHF 74.00n/a3
Nov ’24CHF 69.51
CHF 91.33
+31.4%
15.2%CHF 108.00CHF 74.00CHF 77.303
Oct ’24CHF 77.72
CHF 91.00
+17.1%
18.7%CHF 108.00CHF 74.00CHF 80.002
Sep ’24CHF 79.43
CHF 92.33
+16.3%
15.2%CHF 108.00CHF 74.00CHF 81.003
Aug ’24CHF 79.72
CHF 100.50
+26.1%
5.5%CHF 106.00CHF 95.00CHF 79.702
Jul ’24CHF 77.00
CHF 100.50
+30.5%
5.5%CHF 106.00CHF 95.00CHF 80.002
Jun ’24CHF 79.91
CHF 100.50
+25.8%
5.5%CHF 106.00CHF 95.00CHF 80.402
May ’24CHF 86.19
CHF 94.00
+9.1%
12.8%CHF 106.00CHF 82.00CHF 82.242
Apr ’24CHF 83.33
CHF 94.00
+12.8%
12.8%CHF 106.00CHF 82.00CHF 85.102
Mar ’24CHF 69.27
CHF 86.50
+24.9%
22.5%CHF 106.00CHF 67.00CHF 82.172
Feb ’24CHF 68.83
CHF 86.50
+25.7%
22.5%CHF 106.00CHF 67.00CHF 75.812
Jan ’24CHF 63.42
CHF 86.50
+36.4%
22.5%CHF 106.00CHF 67.00CHF 81.012
Dec ’23CHF 66.76
CHF 86.50
+29.6%
22.5%CHF 106.00CHF 67.00CHF 78.202
Nov ’23CHF 60.79
CHF 86.50
+42.3%
22.5%CHF 106.00CHF 67.00CHF 69.512

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Formycon

€857.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€64.00

7D

3.6%

1Y

15.7%

hVIVO

UK£144.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%